The Real Question Buried Inside Merck Stock’s Premium Price

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

At a glance, Merck (MRK) stock looks pricey. Trading at about 35.3 times the last twelve months of reported earnings, it carries the kind of premium that makes many investors stop looking. But that headline number is not the full story.

Look two years out, and the picture changes completely. On the earnings analysts expect by 2027, that same $128 share price is only about 13.2 times earnings. That is a 63% lower multiple, a steep discount that materializes as projected earnings grow into today's price. For a patient holder, this is the effective price you are paying for the business of 2027. It is crucial to note that part of this drop reflects a difference in accounting: the trailing multiple is based on reported GAAP earnings, while forward estimates typically use a non-GAAP basis that excludes certain charges.

Is the Growth Behind the Discount Believable?

The honest question is never the price tag itself, but whether the growth that creates this discount is likely to arrive. Here, the analyst consensus seems grounded. The forecast calls for revenue to grow about 3.3% a year. That is right in line with the 2.9% revenue growth the company actually delivered over the last twelve months and the 4.9% it posted in the most recent quarter. The projection does not require a heroic leap, just a continuation of current momentum.

Management's own commentary supports this outlook. On its latest earnings call, the company described a portfolio undergoing a "meaningful transformation," driven by the "initial launches of over 20 new products, almost all of which have blockbuster potential." This pipeline is what underpins the forecast for expanding profit margins and robust earnings growth. While analysts expect 2026 earnings of about $2.77 per share, management's own guidance for 2026 non-GAAP EPS is higher, in a range of $5.04 to $5.16, suggesting the one-time charges affecting the analyst consensus number are temporary.

And Merck is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name's growth once the out-year earnings land.

The Margin Of Safety And The Reward

Of course, a stock priced for growth can be volatile. In past market shocks, Merck stock has fallen as much as 62% from its peak. The forward valuation discount offers a cushion, not a guarantee.

If the share price never moves, by 2027 you would simply own the stock at about 13.2 times that year's earnings. This does not produce a gain; it proves you did not overpay for the growth. It is your margin of safety. The actual reward only comes if the market continues to value those earnings at a higher multiple as they arrive. For perspective, if the multiple settles at about 24.3 times, roughly halfway between today's premium and that 13.2 times floor, the stock would be about 84% higher. This kind of forward-looking valuation is crucial for any premium-priced pharmaceutical stock, including peers like Eli Lilly.

What You're Really Paying For

The premium you see on Merck today is not the price a patient investor is really paying. On the earnings expected just two years from now, the valuation becomes quite ordinary. You are not overpaying for the growth story if it unfolds as analysts expect. The potential upside is a separate, conditional layer: if the market keeps awarding the stock anything close to its current multiple as that new earnings base arrives, the price compounds with it. The key thing to watch is the commercial progress of those 20-plus new products, which management believes represent a "potential commercial opportunity of over $70 billion by the mid-2030s." Their success is what turns today's discount into tomorrow's reality.

Own The Growth Without Overpaying

Whether you already hold Merck or you are weighing it now, the appeal is not that the stock is secretly cheap today. It is that you are not overpaying for the growth: on the earnings analysts expect two years out, you are paying an ordinary multiple, even if the price never moves.

The upside sits on top of that. If the market keeps paying anything close to today's multiple as those earnings actually arrive, the price compounds with them. The one catch is that it all rides on a single company's numbers coming through. And if it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that sector, though that still leaves you riding a single slice of the market. That is why the Trefis High Quality (HQ) Portfolio does not lean on any single name: it uses this same valuation-discount discipline to size a measured allocation to strong growth like this, inside a diversified set of 30 high-conviction stocks, re-balanced as the estimates change and with a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000.